Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.

Source:http://linkedlifedata.com/resource/pubmed/id/20818652

Cancer 2011 Jan 15 117 2 421-34

Download in:

View as

General Info

Abstract

The authors demonstrated previously that the combination of topotecan (TPT) and carboplatin (CBP) was more effective than current chemotherapeutic combinations used to treat retinoblastoma in an orthotopic xenograft model. However, systemic coadministration of these agents is not ideal, because both agents cause dose-limiting myelosuppression in children.

PMID
20818652

Publication types

Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural